TB vaccines: Current status and future perspectives

Immunology and Cell Biology

Volumn 87, Issue 4, 2009, Pages 279-286

  Aagaard, Claus ^a   Dietrich, Jes ^a   Doherty, Mark ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Bacterial; BCG; Latency; Tuberculosis; Vaccination

Indexed keywords

BCG VACCINE; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; HYBRID PROTEIN; TUBERCULIN; BACTERIAL ANTIGEN;

ANTIGEN DETECTION; ANTIGEN RECOGNITION; BCG VACCINATION; CLINICAL RESEARCH; CLINICAL TRIAL; EPITOPE MAPPING; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INTERFERON PRODUCTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGY; LUNG TUBERCULOSIS;

ANIMALIA; BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; CLINICAL TRIALS AS TOPIC; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 67449097516     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.14     Document Type: Review

References (118)

1. Maher D, Dye C, Floyd K, Pantoja A, Lonnroth K, Reid A et al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ 2007; 85:341-347.
2. Dolin Pj RM, Kochi A. Global tuberculosis incidenceand mortality during 1990- 2000. Bull World Health Organ 1994; 72: 213- 2 20.
3. al-Kassimi FA, al-Hajjaj MS, al-Orainey IO, Bamgboye EA. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am J Respir Crit Care Med 1995; 152: 1575-1578.
4. ColditzGA, BerkeyCS, Mosteller F, Brewer TF, Wilson ME, Burdick E etal. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96: 29-35.
5. Lanckriet C, Levy-Bruhl D, Bingono E, Siopathis RM, Guerin N. Efficacy of BCG vaccinationofthenewborn: evaluationbyafollow-upstudyofcontactsinBangui. IntJ Epidemiol 1995; 24: 104 2-1049.
6. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998; 2: 200- 207.
7. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Gerorgia. Twent-year evaluation ofcommunitytrial ofBCG vaccination. Public Health Rep 1976; 91: 276- 280.
8. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and earlyadult life. Br Med J 1977; 2: 293- 295.
9. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta- analysis of the literature. Clin Infect Dis 2000; 31 (Suppl 3): S64-S67.
10. Colditz GA, Brewer TF, BerkeyCS, Wilson ME, Burdick E, Fineberg HV etal. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698-70 2.
11. Fine PE, Group KPT. Randomised controlled trial of single BCG, repeated BCG, or combinedBCGandkilledMycobacterium lepraevaccineforprevention ofleprosyand tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996; 348:17- 24.
12. Bjerkedal T. Mycobacterial infections in Norway: a preliminary note on determining their identity and frequency. Am J Epidemiol 1967; 85: 157-173.
13. Dickinson JM, Aber VR, Mitchison DA. Studies on the treatment of experimental tuberculosisoftheguineapigwith intermittentdosesofisoniazid. Tubercle 1973; 54: 211- 2 24.
14. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. AmRevRespirDis 1966; 94:553-568.
15. Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70: 67 2-678.
16. Leung CC, Tam CM, Chan SL, Chan-Yeung M, Chan CK, Chang KC. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. IntJTuberc LungDis 2001; 5:717-7 23.
17. Jassal M, Bishai WR. Extensivelydrug-resistanttuberculosis. LancetInfectDis 2008.
18. Doherty TM. Real world TB vaccines: clinical trials in TB-endemic regions. Vaccine 2005; 23: 2109- 2114.
19. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis(Edinb) 2005; 85: 29-38.
20. Koch R. Fortsetzung der mitteilungen iuber ein heilmittel gegen tuberkulose. Dtsch ed Wochenschr 1891; 17:101-10 2.
21. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006; 13: 179-186.
22. Buddle BM, Wards BJ, Aldwell FE, Collins DM, de Lisle GW. Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine 2002; 20: 11 26-1133.
23. Muller I, Cobbold SP, Waldmann H, Kaufmann SH. Impaired resistance to Mycobac- terium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt- 2+ T ells. Infect Immun 1987; 55: 2037- 2041.
24. Orme IM. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol 1987; 138: 93- 298.
25. Orme IM, Collins FM. Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin. Cell Immunol 1984; 84: 113-1 20.
26. Pedrazzini T, Hug K, Louis JA. Importance of L3T4+ and Lyt- 2+ cells in the immunologic control of infection with Mycobacterium bovis strain bacillus Calm- ette-Guerin in mice. Assessment by elimination of T cell subsets in vivo. J Immunol 1987; 139: 203 2- 2037.
27. Andersen P. Tuberculosis vaccines-an update. Nat Rev Microbiol 2007; 5: 484-487.
28. Reed S, Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect 2005; 7: 9 2 2-931.
29. Kaufmann SH. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 2007; 5: 491-504.
30. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunc- tional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007; 37: 3089-3100.
31. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 2005; 11: S33-S44.
32. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178: 2 243- 2 247.
33. Dorman SE, Holland SM. Interferon-gamma and interleukin-pathway defects and human disease. Cytokine Growth Factor Rev 2000; 11: 3 21-333.
34. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2 249- 2 254.
35. FruchtDM, Holland SM. Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: abnormal IL-regulation. J Immunol 1996; 157: 411-416.
36. JouanguyE, Lamhamedi-Cherradi S, Lammas D, Dorman SE, FondanecheMC, Dupuis S et al. A human IFNGRsmall deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999; 21:370-378.
37. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M et al. Interferon- gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. NEnglJMed 1996; 335: 1956-1961.
38. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R et al. A mutation in the interferon-gamma-receptor gene and susceptibilityto mycobacterial infection. NEnglJMed 1996; 335: 1941-1949.
39. Cowley SC, Elkins KL. CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. JImmunol 2003; 171: 4689-4699.
40. Elias D, Akuffo H, Britton S. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 2005; 99: 363-368.
41. Majlessi L, Simsova M, Jarvis Z, Brodin P, Rojas MJ, Bauche C et al. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Immun 2006; 74: 21 28- 2137.
42. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N et al. Identification of human Tcell antigens for the development of vaccines against Mycobacterium tuberculosis. JImmunol 2008; 7948-7957.
43. Coler RN, Dillon DC, Skeiky YA, Kahn M, Orme IM, Lobet Y et al. Identification of Mycobacterium tuberculosis vaccine candidates using human CD4(+) T-cells expression cloning. Vaccine 2009; 27: 223- 233.
44. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ et al. Multifunctional THcells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-850.
45. Stewart GR, Patel J, Robertson BD, Rae A, Young DB. Mycobacterial mutants with defective control of phagosomal acidification. PLoS Pathog 2005; 1: 269- 278.
46. Weiss DW, Dubos RJ. Antituberculous immunity induced in mice by vaccination with killed tubercle bacilli or with a soluble bacillary extract. J Exp Med 1955; 101: 313-330.
47. Barclay WR, Anacker R, Brehmer W, Ribi E. Effects of oil-treated mycobacterial cell walls on the organs of mice. J Bacte iol 1967; 94: 1736-1745.
48. Orme IM. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect Immun 1988; 56: 3310-331 2.
49. Pal PG, Horwitz MA. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 199 2; 60: 4781-479 2.
50. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994; 62: 2536- 2544.
51. Roberts AD, Sonnenberg MG, Ordway DJ, Furney SK, Brennan PJ, Belisle JT et al. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 1995; 85:50 2-508.
52. Andersen P. TB vaccines: progress and problems. Trends Immunol 2001; 22: 160-168.
53. Andersen P, Heron I. Simultaneous electroelution of whole SDS-polyacrylamide gels for thedirectcellular analysis of complexprotein mixtures. JImmunolMethods 1993; 29-39.
54. Andersen P, Heron I. Specificity of a protective memory immune response against Mycobacterium tuberculosis. Infect Immun 1993; 61: 844-851.
55. Boesen H, Jensen BN, Wilcke T, Andersen P. Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun 1995; 63: 1491-1497.
56. Demissie A, Ravn P, Olobo J, DohertyTM, Eguale T, Geletu M et al. T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts. Infect Immun 1999; 67: 5967-5971.
57. Pollock JM, Andersen P. Predominant recognition of the ESAT-protein in the first phase of interferon with Mycobacterium bovis in cattle. Infect Immun 1997; 65: 2587- 259 2.
58. Borremans M, de Wit L, Volckaert G, Ooms J, de Bruyn J, Huygen K et al. Cloning, sequence determination, and expression of a 3 2-kilodalton-protein gene of Mycobac- terium tuberculosis. Infect Immun 1989; 57: 31 23-3130.
59. Bassey EO, Life PF, Catty D, Gaston JS, Kumararatne DS. T-cell response to mycobacterial proteins: a comparative study of tuberculous and control immunoblots of Mycobacterium tuberculosis and M. bovis BCG. Tuber Lung Dis 1996; 77: 146-153.
60. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000; 68: 791-795.
61. Brodin P, Majlessi L, Brosch R, Smith D, Bancroft G, Clark S et al. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference antigens. J Infect Dis 2004; 190: 115-1 2 2.
62. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM et al. Exchanging ESATwith TB10.in an Ag85B fusion molecule-based tuberculosissubunitvaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174: 633 2-6339.
63. Coler RN, Skeiky YA, Vedvick T, Bement T, Ovendale P, Campos-Neto A et al. Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. JImmunol 1998; 2356- 2364.
64. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-544.
65. Skjot RL, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff TH et al. Epitope mapping of the immunodominant antigen TB10.and the two homologous proteins TB10.and TB1 2.9, which constitute a subfamily of the esat-gene family. Infect Immun 2002; 70: 5446-5453.
66. Skjot RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-family as immunodominant T-cell antigens. Infect Immun 2000; 68: 214- 2 20.
67. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-1 29.
68. Rogerson BJ, Jung YJ, LaCourse R, Ryan L, Enright N, North RJ. Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. Immunology 2006; 118: 195- 201.
69. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 206 2- 2069.
70. Wayne LG, Lin KY. Glyoxylate metabolism and adaption of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 198 2; 37: 104 2-1049.
71. Wayne LG, Sramek HA. Antigenic differences between extracts of actively replicating and synchronized resting cells of Mycobacterium tuberculosis. Infect Immun 1979; 24: 363-370.
72. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003; 48: 833-843.
73. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci USA 2001; 98: 7534-7539.
74. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, DolganovGM, Sherman DR et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. JExpMed 2003; 198: 705-713.
75. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. JExp Med 2004; 200:647-657.
76. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM et al. Transcrip- tional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. JExp Med 2003; 198: 693-704.
77. Downing KJ, Mischenko VV, Shleeva MO, Young DI, Young M, Kaprelyants AS et al. Mutants of Mycobacterium tuberculosis lacking three of the five rpf-like genes are defective for growth in vivo and for resuscitation in vitro. Infect Immun 2005; 73: 3038-3043.
78. Cohen-Gonsaud M, Barthe P, Bagneris C, Henderson B, Ward J, Roumestand C et al. The structure of a resuscitation-promoting factor domain from Mycobacterium tuberculosis shows homology to lysozymes. Nat Struct Mol Biol 2005; 12: 270- 273.
79. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002; 43: 717-731.
80. McKinneyJD, HonerzuBentrupK, Munoz-EliasEJ, MiczakA, Chen B, ChanWTet al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406: 735-738.
81. Schaible UE, Sturgill-Koszycki S, Schlesinger PH, Russell DG. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. JImmunol 1998; 160: 1 290-1 296.
82. Wagner D, Maser J, Lai B, Cai Z, Barry III CE, Honer Zu Bentrup K et al. Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates pathogen-induced microenvironments within the host cell's endosomal system. J Immunol 2005; 174: 1491-1500.
83. Timm J, Post FA, Bekker LG, Walther GB, Wainwright HC, Manganelli R et al. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes inthelungsofchronicallyinfectedmiceandtuberculosispatients. ProcNatlAcadSci USA 2003; 100: 143 21-143 26.
84. Shi L, JungYJ, Tyagi S, GennaroML, NorthRJ. ExpressionofTh1- mediatedimmunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern charac- teristicofnonreplicatingpersistence. ProcNatlAcadSciUSA2003; 100: 241- 246.
85. Olsen AW, van Pinxteren LAH, Okkels LM, Rasmussen PB, Andersen P. Protection of micewithatuberculosissubunitvaccinebasedonafusionproteinofantigen85B and ESAT-6. Infect Immun 2001; 69: 2773- 2778.
86. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb7 2F, delivered as naked DNA or recombinant protein. JImmunol 2004; 172: 7618-76 28.
87. LangermansJA, DohertyTM, VervenneRA, vanderLaanT, LyashchenkoK, Greenwald R et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunitvaccinebasedon afusionprotein ofantigen85B andESAT-6. Vaccine2005; 23: 2740- 2750.
88. Dietrich J, BilleskovR, DohertyTM, Andersen P. Synergisticeffectofbacilluscalmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immuno- genicity and protection. JImmunol 2007; 178: 37 21-3730.
89. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006; 4: 469-476.
90. Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC et al. The protective effectofthe Mycobacterium bovis BCG vaccine is increased bycoadminis- tration with the Mycobacterium tuberculosis 7 2-kilodalton fusion polyprotein Mtb7 2F in M. tuberculosis-infected guinea pigs. Infect Immun 2004; 72: 66 2 2-663 2.
91. KamathAT, RochatAF, Valenti MP, AggerEM, Lingnau K, Andersen P et al. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization withAg85B-ESAT-6intheICadjuvant. PLoSONE 2008; 3:e3683.
92. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7:379-390.
93. Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: howcan webestuseits potential? CurrOpinBiotechnol 2004; 15:506-51 2.
94. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vac- cineprovidespotentprotection from pulmonarytuberculosis. JImmunol2004; 173: 6357-6365.
95. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculo- sisofbacilleCalmette-Guerin vaccineusingmucosal administration andboostingwith a recombinant modified vaccinia virus Ankara. J Immunol 2003; 171: 160 2-1609.
96. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG- primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10: 1 240-1 244.
97. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N et al. Safety and immunogenicity of a new TB vaccine, MVA85A, in M. tuberculosis infected individuals. Am J Respir Crit Care Med 2009.
98. Radosevic K, Wieland CW, RodriguezA, WeverlingGJ, MintardjoR, Gillissen G et al. Protective immune responses to an rAdTB vaccine in two mouse strains (H- 2d vs H- 2b): CDand CDT-cell epitope mapping and role of IFN{gamma}. Infect Immun 2007; 75: 4105-4115.
99. Rooney JF, Wohlenberg C, Cremer KJ, Moss B, Notkins AL. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type glycoprotein D: long-term protection and effect of revaccination. JVirol 1988; 62: 1530-1534.
100. Dhillon J, Mitchison DA. Effect of vaccines in a murine model of dormant tuberculosis. TuberLungDis 1994; 75:61-64.
101. Turner J, Rhoades ER, Keen M, BelisleJT, FrankAA, OrmeIM. Effectivepreexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000; 68: 1706-1709.
102. Repique CJ, Li A, Collins FM, Morris SL. DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 2002; 70: 3318-33 23.
103. Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 2003; 71: 219 2- 2198.
104. Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 269- 271.
105. Zhu D, Jiang S, Luo X. Therapeutic effects of Ag85B and MPTDNA vaccines in a murine model of Mycobacterium tuberculosis infection. Vaccine 2005; 23: 4619-46 24.
106. HaSJ, Jeon BY, Youn JI, Kim SC, ChoSN, SungYC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Therapy 2005; 12: 634-638.
107. DeloguG, Li A, RepiqueC, CollinsF, MorrisSL. DNAvaccinecombinationsexpressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin- conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 2002; 70: 29 2-30 2.
108. Hoft DF, Leonardi C, Milligan T, Nahass GT, Kemp B, Cook S et al. Clinical reactogenicity of intradermal bacille Calmette-Guerin vaccination. Clin Infect Dis 1999; 28: 785-790.
109. Lingnau K, Riedl K, von Gabain A. ICand IC30, novel types of vaccine adjuvant based on peptide deliverysystems. Expert Rev Vaccines 2007; 6: 741-746.
110. Bean AG, Roach DR, BriscoeH, FranceMP, Korner H, Sedgwick JD et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for bylymphotoxin. JImmunol 1999; 162: 3504-3511.
111. Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol2003; 171: 3110-3118.
112. Denis B, Lefort A, Flipo RM, Tubach F, Lemann M, Ravaud P et al. Long-term follow- up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)- alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 2008; 14:183-186.
113. HoftDF, Worku S, Kampmann B, Whalen CC, Ellner JJ, Hirsch CS et al. Investigation of therelationshipsbetween immune-mediated inhibition ofmycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J InfectDis2002; 186: 1448-1457.
114. Snider Jr DE. Ethical issues in tuberculosis vaccine trials. Clin Infect Dis 2000; (Suppl 3): S 271-S 275.
115. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367: 1173-1180.
116. Hoft DF, Tennant JM. Persistence and boosting of bacille Calmette-Guerin-induced delayed-type hypersensitivity. Ann Intern Med 1999; 131:3 2-36.
117. AndersenP, DohertyTM, Pai M, WeldinghK. Theprognosisoflatenttuberculosis: can disease be predicted? Trends Mol Med 2007; 13: 175-18 2.
118. Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, Homolka S et al. High functional diversityin Mycobacterium tuberculosisdriven bygeneticdriftand human demography. PLoS Biol 2008; 6:e311.